# Apogee Therapeutics (APGE) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/APGE
## Company Profile
- Ticker: APGE
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
- Tags: Biologics, Immunology
## Stock Data
- Close: 134.23 USD
- Market cap: 5933897706.25 USD
- Last updated: 2026-08-05
## Business Overview
### Long-Acting I&I Biologics
Apogee Therapeutics develops optimized biologics for inflammatory and immunologic diseases. Its candidates are engineered for differentiated efficacy and extended dosing intervals across large chronic indications.
### Zumilokibart
Zumilokibart is a long-acting antibody targeting IL-13 and is the company's lead program. Its extended half-life is intended to support dosing at intervals measured in months.
### Atopic-Dermatitis Program
The APEX Phase 2 program evaluates induction and maintenance regimens of zumilokibart in moderate-to-severe atopic dermatitis to support Phase 3 dose selection.
### Asthma and Eosinophilic Esophagitis
Following Phase 1b asthma results, Apogee is planning broader development of zumilokibart in asthma and eosinophilic esophagitis, treating the antibody as a pipeline-in-a-product.
### Broader I&I Portfolio
The company is also building biologics for chronic obstructive pulmonary disease and other inflammatory conditions, seeking to improve the dosing and efficacy profiles of validated therapeutic targets.
## Why The Stock Is Moving

As of Aug 5, 2026, APGE was little changed and closed at $134.23. No new same-company headline was identified in the current news window.

## Future Catalysts

- APEX Phase 2 Part B 16-week data for zumilokibart in the second quarter of 2026.
- Initiation of Phase 3 studies of zumilokibart in atopic dermatitis in the second half of 2026.

## Recent News
- 2026-05-28 20:01 EST — [Apogee Therapeutics to Participate in Upcoming June Conferences](https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-june-conferences-d1984190) — Source: Apogee Therapeutics
- 2026-05-27 10:31 EST — [Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart](https://biopharmsignal.com/news/APGE/apogee-therapeutics-announces-1-3-billion-strategic-financing-collaboration-with-d3051363) — Source: Apogee Therapeutics
- 2026-05-27 10:30 EST — [Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis](https://biopharmsignal.com/news/APGE/apogee-therapeutics-announces-positive-16-week-part-b-induction-dose-optimizatio-77f20dd2) — Source: Apogee Therapeutics
- 2026-05-26 20:01 EST — [Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026](https://biopharmsignal.com/news/APGE/apogee-therapeutics-to-host-conference-call-to-report-part-b-16-week-data-from-t-16f5e4cf) — Source: Apogee Therapeutics
- 2026-05-11 11:00 EST — [Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-first-quarter-2026-fi-92ff7d07) — Source: Apogee Therapeutics